Document Detail


Lower urinary tract dysfunction in MS: management in the community.
MedLine Citation:
PMID:  20166471     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lower urinary tract dysfunction in multiple sclerosis is common and is highly amenable to treatment. Individuals may have bladder storage and/or voiding dysfunction. The risk of progression to renal failure is low and hence lower urinary tract dysfunction should be considered medically manageable in most individuals. Evaluation begins with history taking and is supplemented by using a bladder diary. Ultrasonography is used to assess the degree of incomplete bladder emptying, and for assessing upper urinary tract damage. Incomplete bladder emptying is most often managed by clean intermittent self-catheterization and should be initiated if post-void residual urine is greater than 100 mls. Storage symptoms are most often managed using antimuscarinic medications. Other options include desmopressin or detrusor muscle injection of botulinum toxin type A. There are specific situations where specialist urology services should be involved.
Authors:
Jalesh Panicker; Collette Haslam
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of community nursing     Volume:  14     ISSN:  1462-4753     ISO Abbreviation:  Br J Community Nurs     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2010-02-19     Completed Date:  2010-03-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815827     Medline TA:  Br J Community Nurs     Country:  England    
Other Details:
Languages:  eng     Pagination:  474, 476, 478-80     Citation Subset:  N    
Affiliation:
Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, London. j.panicker@ion.ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Antidiuretic Agents / therapeutic use
Botulinum Toxin Type A / therapeutic use
Community Health Nursing / methods*
Deamino Arginine Vasopressin / therapeutic use
Humans
Multiple Sclerosis / complications*
Muscarinic Antagonists / therapeutic use
Neuromuscular Agents / therapeutic use
Nursing Assessment
Referral and Consultation
Risk Factors
Self Care
Urinary Bladder, Overactive / prevention & control
Urinary Catheterization
Urinary Tract Infections / prevention & control
Urination Disorders / diagnosis,  etiology,  prevention & control*
Urodynamics
Chemical
Reg. No./Substance:
0/Antidiuretic Agents; 0/Botulinum Toxin Type A; 0/Muscarinic Antagonists; 0/Neuromuscular Agents; 16679-58-6/Deamino Arginine Vasopressin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overactive bladder syndrome in the older woman: conservative treatment.
Next Document:  Mentoring a student immediately prior to registration: a qualitative study.